7390
W.-S. Huang et al. / Tetrahedron Letters 48 (2007) 7388–7391
bond formation condition (EDCI/HOBt), furnishing
amides 4a and 4b in high yields, respectively.
as opposed to substituted benzaldehydes (HWE reac-
tion) substantially increased the pool of diverse starting
materials and provided access to a number of products
bearing reactive functionalities without the need for pro-
tection/de-protection strategies.
1h
4a
H
O
O
P
R =
N
NH
N
O
N
N
N
References and notes
O
N
1. (a) Boesen, T.; Madsen, C.; Henriksen, U.; Dahl, O. J.
Chem. Soc., Perkin Trans. 1 2000, 2015, and references
cited therein; (b) Cornforth, J.; Wilson, J. R. H. J. Chem.
Soc., Perkin Trans. 1 1994, 1897.
2. Guan, H.-P.; Qiu, Y.-L.; Ksebati, M. B.; Kern, E. R.;
Zemlicka, J. Tetrahedron 2002, 58, 6047, and references
cited therein.
4b
R
NH
Since several N9-(arenethyl)purine compounds have
been reported as potent dual Src/Abl kinase inhibitors9
(e.g., AP23464 has an IC50 < 1 nM against Src kinase),
we were also interested in converting the Heck coupling
product 1 to its saturated analog. As such, 1d was
smoothly hydrogenated to 5 using standard conditions
(H2, Pd/C, EtOAc). Despite a 2-step procedure, this
Heck-hydrogenation route to N9-(arenethyl)purines still
offers significant advantages over the existing methods
for the following considerations: (i) de novo construc-
tion of N9-substituted purines requires early incorpora-
3. Jacobsen, M. F.; Knudsen, M. M.; Gothelf, K. V. J. Org.
Chem. 2006, 71, 9183.
4. (a) Pitha, J.; Ts’o, P. O. P. J. Org. Chem. 1968, 33, 1341;
(b) Taddei, M.; Ciapetti, P. Tetrahedron 1998, 54, 11305.
5. (a) Ziegler, C. B., Jr.; Heck, R. F. J. Org. Chem. 1978, 43,
2949; (b) Busacca, C. A.; Johnson, R. E.; Swestock, J. J.
Org. Chem. 1993, 58, 3239; (c) Datta, G. K.; von Schenck,
H.; Hallberg, A.; Larhed, M. J. Org. Chem. 2006, 71,
3896.
tion of N-9 substituents in
a lengthy reaction
6. (a) Hocek, M. Eur. J. Org. Chem. 2003, 245; (b) Chen, J.;
Grim, M.; Rock, C.; Chan, K. Tetrahedron Lett. 1989, 30,
5543; (c) Tanji, K.; Kubota, H.; Yamamoto, Y.; Higash-
ino, T. Chem. Pharm. Bull. 1987, 35, 4972; (d) Ding, S.;
Gray, N. S.; Wu, X.; Ding, Q.; Schultz, P. G. J. Am.
Chem. Soc. 2002, 124, 1594; (e) Hocek, M.; Votruba, I.;
Dvorakova, H. Tetrahedron 2003, 59, 607; (f) Hocek, M.;
Dvorakova, H. J. Org. Chem. 2003, 68, 5773; (g) Wan, Z.;
Boehm, J. C.; Bower, M. J.; Kassis, S.; Lee, J. C.; Zhao,
B.; Adams, J. L. Bioorg. Med. Chem. Lett. 2003, 13, 1191;
(h) Altmann, E.; Cowan-Jacob, S. W.; Missbach, M. J.
Med. Chem. 2004, 47, 5833; (i) Hocek, M.; Pohl, R.
Synthesis 2004, 2869.
7. Catalysts investigated: 2.5 mol % Pd2(dba)3/5 mol %
Pd[P(t-Bu)3]2, 5 mol % Pd2(dba)3/10 mol % P(o-tol)3.
8. Dai, C.; Fu, G. C. J. Am. Chem. Soc. 2001, 123, 2719.
9. (a) Azam, M.; Nardi, V.; Shakespeare, W. C.; Metcalf, C.
A., III; Bohacek, R. S.; Wang, Y.; Sundaramoorthi, R.;
Sliz, P.; Veach, D. R.; Bornmann, W. G.; Clarkson, B.;
Dalgarno, D. C.; Sawyer, T. K.; Daley, G. Q. Proc. Natl.
Acad. Sci. U.S.A. 2006, 103, 9244; (b) Brunton, V. G.;
Avizienyte, E.; Fincham, V. J.; Serrels, B.; Metcalf, C. A.,
Jr.; Sawyer, T. K.; Frame, M. C. Cancer Res. 2005, 65,
1335; (c) O’Hare, T.; Pollock, R.; Stoffregen, E. P.; Keats,
J. A.; Abdullah, O. M.; Moseson, E. M.; Rivera, V. M.;
Tang, H.; Metcalf, C. A., III; Bohacek, R. S.; Wang, Y.;
Sundaramoorthi, R.; Shakespeare, W. C.; Dalgarno, D.;
Clackson, T.; Sawyer, T. K.; Deininger, M. W.; Druker,
B. J. Blood 2004, 104, 2532; (d) Dalgarno, D.; Stehle, T.;
Narula, S.; Schelling, P.; van Schravendijk, M. R.; Adams,
S.; Andrade, L.; Keats, J.; Ram, M.; Jin, L.; Grossman,
T.; MacNe il, I.; Metcalf, C., III; Shakespeare, W.; Wang,
Y.; Keenan, T.; Sundaramoorthi, R.; Bohacek, R.; Weig-
ele, M.; Sawyer, T. Chem. Biol. Drug Des. 2006, 67, 46.
10. Schaeffer, H. J.; Odin, E.; Bittner, S. J. Pharm. Sci. 1971,
60, 1184.
sequence,10 (ii) SN2 alkylation of 9H-purine with (2-
haloethyl)arenes is often accompanied with significant
b-elimination11 and the pool of commercially available
(2-haloethyl)arenes is very limited, (iii) Mitsunobu reac-
tions of 9H-purine with alcohols suffer from tedious
preparation of (2-hydroxyethyl)arenes and poor yields
due to b-elimination,12 (iv) functional group compatibil-
ities of these existing methods are generally poor.
O
P
NH
N
NH
N
N
N
N
N
N
N
NH
N
N
N
N
O
O
N
H
N
H
CF3
CF3
OH
AP23464
1d
5
To access N9-(arenethyl)purine directly from 2, a reduc-
tive Heck coupling of 2b and iodobenzene in the pres-
ence of HCO2H was attempted.13 Unfortunately, this
reaction did not yield the desired hydroarylation prod-
uct but generated a small amount of Heck product 1,
with the major product being 6-(methylamino)-9-ethyl-
purine. This result suggests that the insertion of ArPdX
complex into N9-vinyl of 2 is slow and that the reduction
of 9-vinylpurine by HCO2H itself predominates, yield-
ing 9-ethylpurine in a manner similar to the reduction
of an enamine in the Leuchart–Wallach reaction.14
In summary, we have demonstrated that 9-vinylpurines
undergo Heck reactions cleanly and efficiently with a
variety of substituted aryl halides.15 Through this reac-
tion, a number of highly potent, purine-based dual
Src/Abl kinase inhibitors bearing 9-(arenethenyl) sub-
stituents were prepared.16 Subsequent hydrogenation
of the Heck reaction products gave rapid access to 9-
(arenethyl)purines. Importantly, the use of aryl halides
11. Raboisson, P.; Lugnier, C.; Muller, C.; Reimund, J.-M.;
Schultz, D.; Pinna, G.; Le Bec, A.; Basaran, H.; Desaubry,
L.; Gaudiot, F.; Seloum, M.; Bourguignon, J.-J. Eur. J.
Med. Chem. 2003, 38, 199.
12. Toyota, A.; Katagir, N.; Kaneko, C. Heterocycles 1993,
36, 1625.
13. Cacchi, S.; Palmieri, G. Synthesis 1984, 575.